ReviewJournal of gynecologic oncology2013
The roles of ARID1A in gynecologic cancer.
Review in Journal of gynecologic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.Oncotarget · 2015Pooled it
- ARID1A deficiency reprograms the tumor secretome, enhancing microenvironmental remodeling and metastatic dissemination in endometrial carcinoma.Cell death & disease · 2026Article
- ARID1A regulates histone octamer transfer activity of human canonical BAF complex.Nucleic acids research · 2025Article
- ARID1A in Gynecologic Precancers and Cancers.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- The roles of chromatin regulatory factors in endometriosis.Journal of assisted reproduction and genetics · 2024Review
- Research progress of SWI/SNF complex in breast cancer.Epigenetics & chromatin · 2024Review
- Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.Journal of biomedical science · 2022Review
- Roles of ARID1A variations in colorectal cancer: a collaborative review.Molecular medicine (Cambridge, Mass.) · 2022Review
- Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.Protein & cell · 2021Review
- Review
- AT-rich interactive domain1A determines sensitivity to oxaliplatin in gastric cancer cells.Translational cancer research · 2020Article
- Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.World journal of clinical oncology · 2020Review
- ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation.Cell reports · 2020Article
- Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.Diagnostics (Basel, Switzerland) · 2020Review
- Proline-Rich Acidic Protein 1 (PRAP1) is a Target of ARID1A and PGR in the Murine Uterus.Development & reproduction · 2019Article
- Expression of PIK3IP1 in the murine uterus during early pregnancy.Biochemical and biophysical research communications · 2018Article
- Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A DeficiencyJournal of Cancer · 2018Article
- New concepts for an old problem: the diagnosis of endometrial hyperplasia.Human reproduction update · 2017Review
- ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance.Human pathology · 2016Article
- Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
One of the exciting findings in recent cancer genome studies is the discovery of somatic mutations in several chromatin remodeling genes. These studies not only illuminate the emerging roles of chromatin remodeling in the pathogenesis of human cancer but also provide molecular genetic basis of aberrant epigenomic regulation as one of the key mechanisms driving cancer development. This is because chromatin remodeling influences a variety of DNA activities such as replication, transcription, repair, methylation, and recombination. Among the mutated chromatin remodeling genes reported, ARID1A is frequently mutated in a variety of human cancers, especially in endometrium-related neoplasms including ovarian clear cell carcinoma, ovarian endometrioid carcinomas, and uterine endometrioid carcinomas, all of which arise from endometrial epithelium. This review will summarize the recent advances in studying the roles of ARID1A mutations in gynecologic cancers with special emphasis on how this new knowledge will further extend our understanding of the pathogenesis of endometrium-related carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.